1. Home
  2. CCLD vs VTYX Comparison

CCLD vs VTYX Comparison

Compare CCLD & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCLD
  • VTYX
  • Stock Information
  • Founded
  • CCLD 1999
  • VTYX 2018
  • Country
  • CCLD United States
  • VTYX United States
  • Employees
  • CCLD N/A
  • VTYX N/A
  • Industry
  • CCLD Computer Software: Prepackaged Software
  • VTYX Medicinal Chemicals and Botanical Products
  • Sector
  • CCLD Technology
  • VTYX Health Care
  • Exchange
  • CCLD Nasdaq
  • VTYX Nasdaq
  • Market Cap
  • CCLD 146.0M
  • VTYX 154.9M
  • IPO Year
  • CCLD 2014
  • VTYX 2021
  • Fundamental
  • Price
  • CCLD $3.39
  • VTYX $9.05
  • Analyst Decision
  • CCLD Buy
  • VTYX Strong Buy
  • Analyst Count
  • CCLD 2
  • VTYX 5
  • Target Price
  • CCLD $3.00
  • VTYX $14.60
  • AVG Volume (30 Days)
  • CCLD 430.1K
  • VTYX 10.1M
  • Earning Date
  • CCLD 11-06-2025
  • VTYX 11-06-2025
  • Dividend Yield
  • CCLD N/A
  • VTYX N/A
  • EPS Growth
  • CCLD N/A
  • VTYX N/A
  • EPS
  • CCLD 0.08
  • VTYX N/A
  • Revenue
  • CCLD $114,315,000.00
  • VTYX N/A
  • Revenue This Year
  • CCLD $6.94
  • VTYX N/A
  • Revenue Next Year
  • CCLD $18.66
  • VTYX N/A
  • P/E Ratio
  • CCLD $45.50
  • VTYX N/A
  • Revenue Growth
  • CCLD 2.97
  • VTYX N/A
  • 52 Week Low
  • CCLD $1.14
  • VTYX $0.78
  • 52 Week High
  • CCLD $4.84
  • VTYX $9.50
  • Technical
  • Relative Strength Index (RSI)
  • CCLD 55.34
  • VTYX 75.00
  • Support Level
  • CCLD $3.13
  • VTYX $8.16
  • Resistance Level
  • CCLD $3.77
  • VTYX $9.46
  • Average True Range (ATR)
  • CCLD 0.17
  • VTYX 0.97
  • MACD
  • CCLD 0.04
  • VTYX 0.20
  • Stochastic Oscillator
  • CCLD 56.28
  • VTYX 95.73

About CCLD CareCloud Inc.

CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: